Equities Analysts Set Expectations for FibroGen Q1 Earnings

FibroGen, Inc. (NASDAQ:FGEN) – Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of FibroGen in a research report issued to clients and investors on Tuesday, March 18th. William Blair analyst A. Hsieh anticipates that the biopharmaceutical company will post earnings of $0.02 per share for the quarter. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. William Blair also issued estimates for FibroGen’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.72) EPS.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $24.91 million.

Several other brokerages also recently weighed in on FGEN. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of FibroGen in a report on Tuesday. StockNews.com assumed coverage on shares of FibroGen in a research note on Friday, March 14th. They set a “hold” rating on the stock.

FibroGen Trading Down 5.9 %

FibroGen stock opened at $0.34 on Thursday. The firm has a market capitalization of $33.91 million, a P/E ratio of -0.27 and a beta of 0.82. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.80. The stock’s fifty day simple moving average is $0.49 and its 200-day simple moving average is $0.43.

Hedge Funds Weigh In On FibroGen

Large investors have recently bought and sold shares of the business. Two Sigma Securities LLC purchased a new stake in FibroGen during the 4th quarter worth about $27,000. Velan Capital Investment Management LP acquired a new stake in shares of FibroGen during the 4th quarter worth about $42,000. XTX Topco Ltd lifted its stake in FibroGen by 423.8% during the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 77,693 shares during the last quarter. Franklin Street Advisors Inc. NC boosted its holdings in FibroGen by 100.0% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 100,000 shares in the last quarter. Finally, FMR LLC increased its stake in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 68,569 shares during the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.